Navigating the Early Clinical Hurdles of T-Cell Engagers in Solid Tumors
- Exploring strategies for widening the therapeutic index in solid tumors, focusing of affinity tuning of CD3 arm and the implementation of logic-gated architectures to protect healthy tissues
- Overcoming physical and metabolic barriers of solid tumor core by integrating costimulatory signals
- Utilizing context-dependent engagers that are only active in hypoxic or acidic conditions